Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma

被引:155
作者
Jang, JW [1 ]
Choi, JY [1 ]
Bae, SH [1 ]
Kim, CW [1 ]
Yoon, SK [1 ]
Cho, SH [1 ]
Yang, JM [1 ]
Ahn, BM [1 ]
Lee, CD [1 ]
Lee, YS [1 ]
Chung, KW [1 ]
Sun, HS [1 ]
机构
[1] Catholic Univ Korea, Coll Med, WHO Collaborating Ctr Viral Hepatitis, Dept Internal Med,Div Hepatol, Seoul 137040, South Korea
关键词
hepatitis B virus; viral reactivation; hepatocellular carcinoma; transarterial chemotherapy;
D O I
10.1016/j.jhep.2004.05.014
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Reactivation of hepatitis B virus (HBV) replication is a well-known complication in cancer patients receiving chemotherapy. The aims of this study were to determine the incidence of HBV reactivation in hepatocellular carcinoma (HCC) patients undergoing transarterial chemo-lipiodolization, and to clarify factors contributing to HBV reactivation. Methods: From April 2001 to September 2002,146 HBsAg positive patients newly diagnosed as HCC were enrolled in the study. Among these, 83 patients underwent transarterial chemo-lipiodolization using epirubicin and/or cisplatin, and 63 received other treatments. Results: In total, HBV reactivation occurred in 30 (20.5%) patients (28 with chemo-lipiodolization and 2 with other treatments), and of the 30 patients, 19 (13.0%) (18 with chemo-lipiodolization and I with other treatments) developed hepatitis. Chemo-lipiodolization was significantly correlated with a higher incidence of hepatitis attributed to HBV reactivation than other treatments (21.7% vs. 1.6%, P < 0.001), irrespective of HBeAg or HBV DNA. Among 83 patients undergoing chemo-lipiodolization, HBV reactivation occurred in 28 (33.7%) patients, and HBeAg seropositivity was the only independent predictor of HBV reactivation (P = 0.013). Three (10.7%) of them died of hepatic decompensation resulting from HBV reactivation. Conclusions: Transarterial chemo-lipiodolization can reactivate HBV, and HBeAg-positive HCC patients receiving chemo-lipiodolization should be closely monitored for HBV reactivation. (C) 2004 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:427 / 435
页数:9
相关论文
共 24 条
  • [11] Nakamura Y, 1996, CANCER-AM CANCER SOC, V78, P2210, DOI 10.1002/(SICI)1097-0142(19961115)78:10<2210::AID-CNCR24>3.0.CO
  • [12] 2-0
  • [13] Steinberg JL, 2000, J MED VIROL, V60, P249, DOI 10.1002/(SICI)1096-9071(200003)60:3&lt
  • [14] 249::AID-JMV1&gt
  • [15] 3.0.CO
  • [16] 2-C
  • [17] Lamivudine therapy for hepatitis B virus reactivation in a patient receiving intra-arterial chemotherapy for advanced hepatocellular carcinoma
    Tamori, A
    Nishiguchi, S
    Tanaka, M
    Kurooka, H
    Fujimoto, S
    Nakamura, K
    Shiomi, S
    [J]. HEPATOLOGY RESEARCH, 2003, 26 (01) : 77 - 80
  • [18] MASSIVE HEPATIC-NECROSIS AFTER CHEMOTHERAPY WITHDRAWAL IN A HEPATITIS-B VIRUS CARRIER
    THUNG, SN
    GERBER, MA
    KLION, F
    GILBERT, H
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1985, 145 (07) : 1313 - 1314
  • [19] Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product
    Usuda, S
    Okamoto, H
    Iwanari, H
    Baba, K
    Tsuda, F
    Miyakawa, Y
    Mayumi, M
    [J]. JOURNAL OF VIROLOGICAL METHODS, 1999, 80 (01) : 97 - 112
  • [20] Hepatitis B virus reactivation after a single session of transarterial chemoembolization in patients with hepatocellular carcinoma
    Vizzini, GB
    Luca, A
    Marino, IR
    [J]. ANNALS OF INTERNAL MEDICINE, 2003, 138 (08) : 691 - 692